About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, June 13th, 2017

The QualityStocks
Daily Stock List


Cannabis Sativa, Inc. (CBDS)

Promotion Stock Secrets, Jason Bond, Marketbeat, TopPennyStockMovers, Stockgoodies, Top Pros’ Top Picks, Insider Financial, Darwin Investing Network, Wall Street Mover, Stock Beast, Cannabis Financial Network News, Greenbackers, TheMicrocapNews, TopStockAnalysts, Flagler Financial Group, smartOTC, and Real Pennies reported on Cannabis Sativa, Inc. (CBDS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Cannabis Sativa, Inc. engages in branding and licensing through its 'hi' intellectual properties. The Company engages, via its subsidiaries, Wild Earth Naturals and "hi" Brands International, Inc., in the research, development, and licensing of specialized natural products. These include formulas, edibles, topicals, recipes, and delivery systems. Cannabis Sativa has been active in pursuing Intellectual Property (IP). It has successfully acquired an increasing portfolio of IP. Cannabis Sativa is headquartered in Mesquite, Nevada.

The Company brands, licenses, innovates, as well as markets premier plant-derived topical creams, transdermals, balms, sublinguals, lubricants, and edibles for medical and recreational marijuana consumers, and legal nutraceuticals and branded merchandise for consumers in general. Its goal is to license the "hi" brand to distributors and producers of quality products and to other ancillary participants in the retail cannabis industry.

Cannabis Sativa has its Wild Earth Naturals offerings. It offers the Wild Earth Naturals line of CBD Water and cosmetic products designed to use organic and natural ingredients. These include CBD and hemp seed oil. Cannabis Sativa’s wholly-owned subsidiary, Hi Brands International, entered into an agreement with Centuria Natural Foods, Inc. to market their proprietary CBD Rich Hemp Oil products. Their CBD capsules are marketed under the name, "hi CBD."

Cannabis Sativa has acquired a majority ownership interest in iBudtender, Inc., a Colorado corporation. Cannabis Sativa also entered into an agreement to acquire a 49 percent ownership interest in a nine-acre property in Los Angeles County, California. The ownership group’s plan is to lease the property to an industrial hemp farm operator. The operator will conduct farming activities under the Industrial Hemp provisions of California's Adult Use Marijuana Act (Prop 64).

Recently, Cannabis Sativa announced that it entered into a license agreement for the manufacture, marketing, and sale of its White Rabbit products in California. Cannabis Sativa foresees adding products to its California licensing agreement in the coming months. In addition, the Company is looking to engage additional licensees in states where medical cannabis is legal.

Cannabis Sativa closed its acquisition of the White Rabbit brand of cannabis sprays and cannabis mints. This acquisition includes the exclusive and proprietary product formulations, product mixes, manufacturing methods, and branding. The White Rabbit product line now comprises fast-acting low dose cannabis oral sprays and low dose cannabis mints.

Cannabis Sativa has developed a "hi" branded infused honey product (hi honey) made from rich African honey and infused with CBD or THC. Mr. David Tobias, Company President, said that "the hi honey flavor is rich, dark and unique." He furthermore expressed his belief that "superfood honey contains powerful compounds including probiotics and polyphenols, which could help fight inflammation and protect cells from damage."

Cannabis Sativa, Inc. (CBDS), closed Tuesday's trading session at $3.65, up 12.31%, on 115,751 volume with 354 trades. The average volume for the last 60 days is 72,988 and the stock's 52-week low/high is $1.52/$9.50.

SolarWindow Technologies, Inc. (WNDW)

TopPennyStockMovers, AllPennyStocks, Stock Oodles, Winston Small Cap, Stock Gumshoe, and SmallCapVoice reported previously on SolarWindow Technologies, Inc. (WNDW), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

SolarWindow Technologies, Inc. is a developer of next generation, transparent electricity-generating SolarWindow™ coatings. Its corporate mission has been to create SolarWindow™ products, which produce substantial amounts of clean electricity, financially reward its customers, and benefit the environment. SolarWindow™ is the subject of a patent pending technology. The Company previously went by the name New Energy Technologies, Inc. It changed its name to SolarWindow Technologies, Inc. in March of 2015. SolarWindow Technologies has its headquarters in Columbia, Maryland.

SolarWindow™ uses organic materials dissolved into liquid, best for low-cost high-output manufacturing. SolarWindow™ systems can undergo installation on the readily-available sizeable window glass surfaces on tall towers and skyscrapers. SolarWindow™ can be applied to the sides of tall towers, generating electricity using natural, shaded, and artificial light. SolarWindow™ coatings generate electricity on see-through glass and flexible plastics with colored tints popular to skyscraper glass.

SolarWindow™ products are undergoing development to be installed on all four sides of a skyscraper. This turns the whole building into a power generator. The Company’s latest products will be engineered as transparent, tinted, flexible veneers that installers can apply directly over top of existing windows on tall towers and skyscrapers. This expanded product line extends its market reach beyond new and replacement installations, to include windows now installed on the estimated five million commercial buildings constructed in the United States alone.

SolarWindow Technologies entered Phase III of its Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Energy’s National Renewable Energy Laboratory (NREL). The principal development goal of the Agreement is the commercialization of SolarWindow™ products. SolarWindow™ is also expanding product development to include applying its electricity-generating coatings onto flexible glass – as thin as a business card (only 0.1-millimeter-thick) that is flexible enough to be bent without breaking or cracking.

Last month, SolarWindow Technologies announced the successful completion of important freeze/thaw performance testing required for the commercialization of the Company’s transparent electricity-generating coatings that could turn ordinary passive glass into electricity-generating windows. These transparent, electricity-generating coatings have the potential of turning new and existing tall buildings into ‘clean power generators.’

SolarWindow™ - upon application to a 50-story building, for example - could decrease electricity costs by up to 50 percent annually and realize a one-year financial payback, according to independently-validated modeling.

Furthermore, in May, SolarWindow Technologies announced that its transparent electricity-generating glass has been successfully processed via the rigorous autoclave system for window glass lamination at a commercial window fabricator. Glass modules (layered with SolarWindow™ electricity-generating liquid coatings) were subjected to the extremely high heat and pressure of autoclave equipment located at the fabricator's facility.

Despite the SolarWindow™ modules being subjected to the harsh pressure and temperature conditions, subsequent performance testing confirmed that the modules continued to produce power, setting the path for deployment of the Company’s electricity-generating windows.

SolarWindow Technologies, Inc. (WNDW), closed Tuesday's trading session at $2.94, up 1.38%, on 32,776 volume with 97 trades. The average volume for the last 60 days is 37,933 and the stock's 52-week low/high is $2.00/$4.16.

MRI Interventions, Inc. (MRIC)

Wall Street Resources, Real Pennies, and FeedBlitz reported earlier on MRI Interventions, Inc. (MRIC), and today we report on the Company, here at the QualityStocks Daily Newsletter.

MRI Interventions, Inc. is a medical device company that develops and commercializes distinct platforms for performing minimally invasive surgical procedures in the brain under direct, intra-procedural magnetic resonance imaging, or MRI, guidance. Employing a hospital's existing MRI suite, the design of its Food and Drug Administration (FDA)-cleared and CE-marked ClearPoint® system is to enable a range of minimally invasive procedures in the brain. MRI Interventions is headquartered in Irvine, California and the Company’s shares trade on the OTC Markets’ OTCQB.

MRI Interventions has a co-development and co-distribution agreement with Brainlab, a leader in software-driven medical technology, regarding the ClearPoint® system. ClearPoint® is an integrated system of hardware components, disposable components, and intuitive, menu-driven software.

The ClearPoint® system enables real-time MRI-guided navigation for a wide assortment of minimally-invasive neurosurgery procedures. This platform is especially well-matched for facilitating drug delivery directly to brain tumors. The ClearPoint® system is the only navigation platform designed to allow real-time visualization during minimally-invasive neurosurgical procedures.

The ClearPoint® system provides MRI-based stereotactic guidance for the placement and operation of instruments or devices during the planning and operation of neurological procedures performed within the MRI suite. ClearPoint® procedures can be used with 1.5T and 3T scanners.

Moreover, MRI Interventions is developing the ClearTrace® system in partnership with Siemens Healthcare. This is to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation.

In April, MRI Interventions announced it signed a joint development agreement with Mayo Clinic to design, develop, and also commercialize MRI-guided, minimally invasive therapies for stroke. The initial emphasis of the collaboration is the development and commercialization of a novel, MRI-guided product for the treatment of intra cerebral hemorrhage (ICH).

In addition, MRI Interventions announced in April that it signed a license and collaboration agreement with Acoustic MedSystems, Inc. (AMS).  With this agreement, MRI Interventions and AMS will co-develop real-time, MRI-guided ultrasonic ablation therapies with an initial focus on the treatment of pancreatic cancer.  Development of these therapies will further expand the capabilities and addressable market for MRI Interventions’ ground-breaking MRI-guided surgical platform. Acoustic MedSystems is a foremost developer of novel ultrasound ablation technologies and systems.

Recently, MRI Interventions announced that Mr. John Fletcher was appointed to the Company’s Board. Mr. Fletcher, Founder and Managing Partner of Fletcher Spaght, Inc., brings over 30 years of experience in healthcare with a concentration in the medical devices field.  He succeeds Mr. Andrew K. Rooke, who stepped down from MRI Interventions’ Board after close to six years of exceptional service to the Company.

MRI Interventions, Inc. (MRIC), closed Tuesday's trading session at $3.60, down 5.26%, on 11,867 volume with 61 trades. The average volume for the last 60 days is 4,911 and the stock's 52-week low/high is $1.99/$14.00.

GrowGeneration Corp. (GRWG)

MarketWatch, Barchart, and OTC Markets reported on GrowGeneration Corp. (GRWG), and today we report on the Company, here at the QualityStocks Daily Newsletter.

GrowGeneration Corp. is one of the largest specialty retail hydroponic and organic gardening store chains. The Company sells to the commercial and home cannabis markets. GrowGeneration is an online and offline resource for professional growers. Its plan is to be a grow pioneer's single-source outfitter for the latest in top-notch growing products, options, ideas and more. GrowGeneration’s mission is to own and operate GrowGeneration branded stores in all the major legalized cannabis states. The Company has its corporate office in Denver, Colorado.

GrowGeneration carries and sells thousands of products. These include organic nutrients and soils, and advanced lighting technology. Products also include state-of-the-art hydroponic equipment to be used indoors and outdoors by commercial and home growers.

GrowGeneration signed a 5-year lease on a 10,000-square foot facility in Las Vegas, Nevada (its 12th store). This location is a retail and warehouse location. It serves the growing number of commercial and home growers in the Nevada market. GrowGeneration’s Las Vegas store officially opened its doors on January 17, 2017.

The Company and New Frontier Data have partnered to provide cultivators in the sector with the essential data to help them better understand where their time, resources, and money should be spent to best align with product demand and maximize profitability at a critical time in this developing sector.

New Frontier Data is the authority in real time business intelligence for the cannabis industry. GrowGeneration will provide historical and real-time sales data to New Frontier Data to create a "State of the Ancillary Market" report.

GrowGeneration signed a 5-year lease on a 13,000-square foot facility in Denver, Colorado for its 12th store. The Denver South location will serve as a retail and warehouse location, and GrowGeneration’s headquarters. It will serve the increasing number of commercial and home growers in the Denver market.
Also, GrowGeneration entered into a 5-year lease for a 7,300-sq. ft. facility in Trinidad, Colorado. It will replace and consolidate its existing 3,000 sq. ft. Trinidad store as the Company's new center for the Trinidad and New Mexico markets.

GrowGeneration has acquired all the assets of Sonoma Hydro. It signed a 5-year lease on an 8,000-square foot facility in Santa Rosa, California. The Sonoma Hydro location, one of the original hydroponic stores in what is named the Emerald Triangle, will serve as a retail and warehouse location serving the growing number of commercial and home growers in the Northern California market.

This past April, GrowGeneration announced that it signed a three-year lease, with 2 three-year renewals, on an 8,000-square foot facility in San Bernardino, California. This is the 13th location for the Company, and the second in California.

Last month, GrowGeneration announced it acquired all the assets of Seattle Hydro Spot. It also signed a three-year lease on a 4,000-square foot retail and warehouse facility in Seattle, Washington. The Seattle Hydro Spot location, one of the original hydroponic stores in what is called the Ballard neighborhood of Seattle, will serve as a retail and warehouse location servicing the increasing number of commercial and home growers in the Northwest market.

GrowGeneration Corp. (GRWG), closed Tuesday's trading session at $1.9909, down 2.88%, on 27,536 volume with 59 trades. The average volume for the last 60 days is 18,298 and the stock's 52-week low/high is $1.50/$3.43.

Bearing Lithium Corp. (BRGRF)

TradingView, MarketWatch, and InvestorsHub reported on Bearing Lithium Corp. (BRGRF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Bearing Lithium Corp. is a mineral exploration and development company. It focuses predominantly on lithium. By way of an agreement with Li3 Energy, Inc. (LIEG), Bearing Lithium will acquire an undivided 17.7 percent interest in the advanced-stage Maricunga lithium brine project in Chile. This represents one of the highest-grade development opportunities in the Americas. Bearing Lithium is based in Vancouver, British Columbia,

As of May 9, 2017, the Maricunga Lithium Project has had more than US$25 million of exploration. All future expenditures through to the delivery of a Definitive Feasibility Study (DFS) are fully-funded by its Joint Venture (JV) partners. Bearing Lithium is now centered on identifying, advancing, and de-risking lithium projects. The Company carries out all facets of exploration and development. This is from grassroots prospecting to feasibility studies.

Bearing Lithium’s other projects include Fish Lake Valley and the HY/Jay project. The Fish Lake Valley Lithium property is in Esmeralda County, Nevada. It comprises a contiguous 1,620-acre package of 81 lode claims. The HY/Jay project is in the Upper Hyland River area of eastern Yukon in a belt that hosts several high-grade gold vein occurrences. This includes the 3Ace property currently undergoing exploration by Golden Predator Mining Corp.

The HY claim group was acquired from Freeport McMoRan Exploration in 2011. Freeport retains a 2-per-cent net smelter royalty (NSR) payable to Freeport that can be reduced to a 1-per-cent NSR through a one-time payment of $1 million. In 2011, The HY claim group was subsequently expanded by the addition of the Jay claims through staking.

In March of this year, Bearing Lithium announced it received results from Li3 Energy from the pilot evaporation ponds at the Maricunga lithium brine project. Bearing entered into a definitive agreement to acquire Li3 and its interest in the Maricunga Project. Presently, Li3 holds the 17.7 percent interest in the Maricunga Project along with Minera Salar Blanco (MSB) and Lithium Power International Limited at 32.3 percent and 50 percent respectively pursuant to the JV arrangement.

Bearing Lithium has also received an update from Li3 Energy from the continuing process testing at the Maricunga lithium brine project. Under the terms of the JV, Lithium Power has agreed to fund exploration and development costs with Li3 and MSB having a free carry until the completion of a definitive feasibility study.

Bearing Lithium Corp. (BRGRF), closed Tuesday's trading session at $0.729, up 11.03%, on 713,639 volume with 266 trades. The average volume for the last 60 days is 10,046 and the stock's 52-week low/high is $0.3036/$1.4111.


The QualityStocks
Company Corner


Converde Energy USA, Inc. (XFUL)

The QualityStocks Daily Newsletter would like to spotlight Converde Energy USA, Inc. (XFUL). Today, Converde Energy USA, Inc. closed trading at $0.00485, up 7.78%, on 367,598 volume with 14 trades. The stock’s average daily volume over the past 60 days is 1,615,606, and its 52-week low/high is $0.0002/$0.10.

Converde Energy USA, Inc. announced today that on June 6, 2017, it entered into a Securities Purchase Agreement with GPL Ventures LLC ("GPL") in which GPL may purchase common stock equal to a value of up to Three Million Dollars ($3,000,000) when XFUL has qualified the necessary number of shares under Regulation A through an offering statement (Form 1-A). XFUL intends on filing the offering statement within the next thirty days.

Converde Energy USA, Inc. (XFUL), d/b/a American Energy Partners Inc., and its group of companies are dedicated to delivering solutions wherever energy production and water meet technology. The company has positioned itself to benefit from above-favorable margins on each of its subsidiaries due to the synergy of the chain of revenues.

Hydration Company of PA (HCPA)
Hydration Company of PA focuses on sourcing, implementing and distributing reclaimed water at a profit. This subsidiary's competitive advantage mainly lies within its pure volume of reclaimed water and its access to low cost treatment with high flow rates and highly concentrated solids through the technologies of XFUL's partners. Because of the volume as well as the flexibility of the model established via patent pending methodology and conveyance methods, HCPA can effectively gain market share immediately as large corporations prefer access to one source that can supply massive amounts of reclaimed water regardless of drought conditions.

American Energy Solutions, LLC
American Energy Solutions, LLC utilizes a network of partners to provide off-the-shelf and custom-designed treatment technologies that contribute to HCPA's business model of low-cost treatment and distribution. As a provider of design, this subsidiary is capable of repeatable and synergistic services across the value chain. American Energy's long-term plan is to utilize an in-house team to grow market share as water use continues to become more critical to modern industry.

Gilbert Oil & Gas Company
Gilbert Oil & Gas Company is leveraging broad industry valuation experience to move forward on its mission to add shareholder value through drilling, operating, and partnership opportunities in the upstream oil and gas space. Equipped with the in-house capabilities necessary to source and evaluate opportunities for profitability, Gilbert is positioned to become a strong customer of XFUL's other subsidiaries, providing them with the foundation to attract other customers and enter new markets.

Integrated Business Strategy
By combining ownership of water sources via Hydration Company of PA, design and treatment solutions via American Energy Solutions, and a stream of promising opportunities via Gilbert Oil & Gas Company, XFUL is essentially creating a positive revenue feedback loop. This synergistic business model also opens opportunity for higher profit margins, additional revenue, and faster growth in new markets. Disclaimer

Converde Energy USA, Inc. Company Blog

Converde Energy USA, Inc. News:

Converde Energy USA, Inc. to Receive up to $3M Investment from GPL Ventures, LLC

Converde Energy USA, Inc. to Receive up to $3M Investment from GPL Ventures, LLC

Converde Energy USA, Inc. (XFUL) is “One to Watch”

Patriot One Technologies, Inc. (PTOTF)

The QualityStocks Daily Newsletter would like to spotlight Patriot One Technologies, Inc. (PTOTF). Today, Patriot One Technologies, Inc. closed trading at $0.62, up 4.29%, on 115,798 volume with 60 trades. The stock’s average daily volume over the past 60 days is 72,283, and its 52-week low/high is $0.4665/$1.49.

Patriot One Technologies, Inc. developer of the award-winning PATSCAN CMR™ concealed weapons detection system, is pleased to report that in the three months since product marketing began during the lead up to the ISC West trade show in Las Vegas, confirmed sales commitments now top $2.7 million.

Patriot One Technologies, Inc. (PTOTF) is leveraging seven years of development to create powerful technologies that mitigate security risks by detecting concealed weapons via novel radar technology.

Developed through a NATO-funded project at McMaster University, Patriot One's disruptive NForce CMR1000 technology is the first cost-effective solution available for active shooter prevention, the need for which is evidenced by an increasing number of active shooter events in the United States and worldwide.

A recent study that surveyed data going back as far as 1966 demonstrates that there have been significantly more mass shootings in the U.S. than any other country for decades. Statistics for the 46-year period shows that even though America only holds 5% of the world's population, it took count of 31% of all public mass shootings. According to the FBI, there were an astounding 160 incidents from 2000 to 2013 that resulted in 486 people killed and 557 wounded. In years 2014 and 2015, there were nearly six times as many incidents compared to 2000 and 2001. The disturbing trend shows that there will be increasingly more incidents if better preventative measures aren't taken.

Patriot One's patent-pending solution to this alarming progression enables stand-off detection, even on moving targets, with a "cognitive" ability to learn and identify new threats once deployed. The product is not intended to threaten the constitutional rights of legal gun carriers, and it is also void of privacy and health concerns of traditional detection technologies, which require subject compliance, present false positives, and are often slow, inefficient and costly.

In contrast, Patriot One's technology is small in size and can be "covertly" placed in a doorway or hallway to prevent planned attacks in public places like schools, concerts, stadiums, banks, airports, offices, hospitals, shopping centers and other facilities for which there are concerns. With this method of deployment, there is no subject compliance requirement. In addition, because an image of the target is not generated, there are also no privacy concerns. Detection is real-time and entirely computer-based, which means there is no need for human operators to alert security. This eliminates the safety concerns of a would-be operator, reduces the expense of a human operator, and enables overall accuracy of 93%.

The technology is designed to identify if someone is carrying a gun, knife, suicide vest, etc., by analyzing metal content and relating it to a database of known weapon signatures. Patriot One believes the widespread use of this detection technology could act as an effective deterrent, thereby diminishing the epidemic phenomena of active shooters across the nation and around the world.

The company is guided by a team of experts in the areas of high-frequency electromagnetics, counter-terrorism, conflict resolution, government/corporate interface, sensor development, proactive security and business development. Senior Management has partnered with, among other affiliates, Ridge Global, which was founded by recently appointed advisory board member Tom Ridge, the first head of the Department of Homeland Security, first U.S. Secretary of Homeland Security, and 43rd governor of Pennsylvania.

Along with its partners, Patriot One is addressing global concerns of active shooting events and other violent terrorist attacks. The key is to short-circuit the event through effective prevention technologies and security protocols. Disclaimer

Patriot One Technologies, Inc. Company Blog

Patriot One Technologies, Inc. News:

Patriot One Marks 3-Months of Global PATSCAN Sales with $2.7M in Signed Agreements

Patriot One Appoints Former Senior Counter Terrorism Official John Gillies to Board

Patriot One and SENGEX Accelerate PATSCAN Delivery to U.S. Government Agencies

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.3085, off by 3.59%, on 717,418 volume with 226 trades. The stock’s average daily volume over the past 60 days is 1,047,772, and its 52-week low/high is $0.05/$0.72.

InMed Pharmaceuticals, Inc. is pleased to announce it has signed an agreement with Pharmaseed Ltd, Israel's largest GLP-certified pre-clinical contract research organization, to develop a final formulation for InMed's lead compound, INM-750, a proprietary, topical cannabinoid product candidate intended as a therapy in epidermolysis bullosa and other potential dermatological and wound-healing applications. "This agreement with Pharmaseed now adds one of Israel's leading formulation development teams to our efforts and represents an important strategic relationship as we move INM-750 towards our first clinical trial," stated Eric A. Adams, CEO of InMed.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Announces Agreement to Advance a Topical Formulation of INM-750

InMed Raises $5.75 Million Through Underwritten Financing Including Full Exercise of the Over-Allotment Option

InMed Pharmaceuticals Files Provisional Patent Application for Ophthalmic Drug Delivery

India Globalization Capital, Inc. (IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital, Inc. (NYSE: IGC). Today, India Globalization Capital, Inc. closed trading at $0.44, up 3.53%, on 125,612 volume with 339 trades. The stock’s average daily volume over the past 60 days is 327,387, and its 52-week low/high is $0.19/$0.80.

India Globalization Capital, Inc. (IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.

The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.

IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.

Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.

Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings. Disclaimer

India Globalization Capital, Inc. Company Blog

India Globalization Capital, Inc. News:

IGC Acquires Exclusive Rights to THC-based treatment for Alzheimer’s Disease

India Globalization Capital, Inc. (NYSE: IGC) Taps Dr. Craig Cheifetz as Advisor for Clinical Trials of Cannabis-Based Combination Therapies

NetworkNewsWire Announces Editorial Discussing the Potential of Cannabis-Based Therapies for Pain Management

BlastGard International Inc. (BLGA)

The QualityStocks Daily Newsletter would like to spotlight BlastGard International Inc. (BLGA). Today, BlastGard International Inc. closed trading at $0.02, even for the day, on 60,900 volume with 6 trades. The stock’s average daily volume over the past 60 days is 103,371 and its 52-week low/high is $0.004/$0.03.

BlastGard International Inc. (BLGA) is a manufacturer and distributor of protective products for military and law enforcement personnel. The Corporation operates under two segments, BlastGard Defense Group and Highcom Security.

Blastguard is a blast mitigation specialist with proprietary material proven to effectively mitigate blasts and suppress fires resulting from explosions. The company's patented BlastWrap® technology acts as a "virtual tent" to effectively mitigate blast effects and suppress post-blast fires. This unique technology works by triggering physical and chemical processes to dissipate blast energy, thereby reducing the aftermath of acoustic and shock waves, peak overpressure, reflected peak overpressure, impulse and afterburn. The remaining, significantly reduced energy is transmitted at a slower, more sustainable level. Notably, BlastWrap does not dispense chemical extinguishants; uses neither alarms, sensors, nor an activation system; and is nontoxic and ecologically friendly.

Similarly, the company's BlastGard MTR trash receptacles dramatically reduce lethal threats posed by the detonation of an improvised explosive device (IED). Equipped with Triple Wall Technology, BlastGard MTR mitigates primary fragments, secondary fragments, mechanical effects (shock/blast pressure) and thermal effects (contact and radiation burn) from the fireball, after-burn and resultant post-blast fires.

BlastGard's primary market focus lies on providing blast effects mitigation solutions for customers operating in the commercial sector, military, law enforcement and government agencies. With a vision of being recognized as the leading provider of environmentally responsible solutions to protect lives and structures from the hazards associated with fire and explosions, the company is capable of addressing a wide array of industry applications spanning from fire suppression for naval vessels and merchant ships to protection of buildings against vehicle bombs.

This vision is supported by the ban of Halon extinguishing agents, as outlined in the Montreal protocol, which effectively establishes BlastWrap® as the only blast and fire suppression means available for most applications, including adaptation for underwater use.

The company's position at the head of the blast suppression market has helped BlastGard attain a number of government awards, including designation of its BlastWrap® product as a Qualified Anti-Terrorism Technology and placement on the "Approved Products List for Homeland Security." This designation was extended in early 2017, meaning that BlastWrap® is approved for use by the Department of Homeland Security under the SAFETY Act until November 2021.

HighCom Security, develops, tests, manufactures and distributes body armor and personal protective equipment, including more than two dozen NIJ (National Institute of Justice) compliant hard and soft armor products. Highcom Security has a 20-year history of producing quality armor with no operational failures and no recalls of its American made products.

Highcom Security was founded in 1997 and has produced close to 1 million pieces of armor for the Global community. The company is ISO 9001:2008 certified and the first company in the world to be BA 9000:2012 certified compliant.

For the past decade, Highcom Security has also been able to offer some of the largest armor manufacturers with private label/OEM hard armor solutions for end use by military and law enforcement agencies globally, a market reach obtained because of the company's reputation for innovative technology, exceptional customer service and superior quality performance. Disclaimer

BlastGard International Inc. Blog

BlastGard International Inc. News:

BlastGard International Inc. (BLGA) is “One to Watch”

BlastGard International Addresses Company's Trading Activity

Big Trading Volumes for BlastGard International Initiates Due Diligence Report


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



OnPoint Stock Alert
(ITDN) +209.09%


(HRMNW) +60.50%


(MOSY) +32.21%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251